Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|June 3, 2025

Using Ultrasensitive PSA Assays in Routine Practice

Author(s)Neal Shore, MD, FACS

Explore the potential of ultra-low PSA testing in managing metastatic hormone-sensitive prostate cancer, balancing accessibility and cost considerations.

Episodes in this series

EP. 1 An Overview of the ARANOTE Trial

EP. 1 An Overview of the ARANOTE Trial

1 expert in this video

EP. 2 Comparing Trials Studying Treatment Intensification In mHSPC

1 expert in this video

EP. 3 Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

1 expert in this video

EP. 4 Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

1 expert in this video

EP. 5 Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

1 expert in this video

EP. 6 Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC

1 expert in this video

EP. 7 Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point

1 expert in this video

EP. 8 Using Ultrasensitive PSA Assays in Routine Practice

1 expert in this video

EP. 9 The Use of Ultra-Low PSA in Specific Patient Profiles

1 expert in this video

EP. 10 Selecting Between Receptor Pathway Inhibitors for mHSPC

Practical Considerations for Ultrasensitive PSA Testing

Key Themes:

Feasibility of implementing ultrasensitive PSA assays in community practice
Logistical challenges including cost and standardization
Clinical interpretation considerations

Expert Insights:

Dr Shore addressed the practicality of using ultrasensitive PSA assays in routine clinical practice.

The discussion covered pros and cons, cost implications, assay standardization challenges, and the nuances of clinical interpretation.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Surabhi Amar, MD, MHA, MBBS; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

FDA approves first-line Zenflow system for the treatment of BPH

Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC

FDA approves gepotidacin for uncomplicated urogenital gonorrhea

© 2025 MJH Life Sciences^®

All rights reserved.